Sanam Parikh
About Sanam Parikh
Sanam Parikh, age 27, served as an independent director of Tharimmune, Inc. beginning November 2024 and resigned on November 6, 2025 in connection with financings; the resignation was not due to any disagreement with the company . He holds a B.S. in Biology (New Jersey Institute of Technology) and an MPH (Rutgers), with clinical research and project management experience, most recently as a Clinical Trial Manager at Schrödinger since March 2022 .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Schrödinger | Clinical Trial Manager | Since March 2022 | Clinical trial operations experience |
| Clario | Assistant Project Manager | Not disclosed | Project management |
| Q Answer Lab | Lab Technologist | Not disclosed | Laboratory operations |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| None disclosed | — | — | No other public company directorships disclosed . |
Board Governance
- Independence: Board determined Parikh was an “independent director” under Nasdaq rules .
- Committee assignments: As of year-end 2024, audit, compensation, and nominating committees were composed of other directors; no Parikh committee assignment disclosed in the proxy .
- Attendance: In 2024, no director attended fewer than 75% of board and committee meetings; Parikh joined late-2024, with no specific attendance disclosure for him .
- Tenure: Director from November 2024 until resignation November 6, 2025 .
- Lead independent director: Not disclosed .
Fixed Compensation
Director cash compensation structure (2024 policy):
| Component | Amount (USD) | Notes |
|---|---|---|
| Annual board retainer | $65,600 | Paid quarterly |
| Audit committee chair | $15,000 | Additional to retainer |
| Audit committee member | $7,500 | Additional |
| Compensation committee chair | $8,000 | Additional |
| Compensation committee member | $4,000 | Additional |
| Nominating committee chair | $6,000 | Additional |
| Nominating committee member | $3,000 | Additional |
Equity grant policy for non-employee directors: initial appointment grants of options to purchase up to 2,553 shares, vesting monthly over one year; annual meeting grants as determined by the compensation committee .
Performance Compensation
- Director compensation is primarily cash retainers plus equity options; no director-specific performance metrics disclosed for Parikh’s compensation .
- Company plan permits performance-based awards (RSUs/other stock-based awards) generally, with change-in-control and clawback provisions; this is plan-level, not Parikh-specific .
Recent option awards to Parikh (Form 4):
| Grant Date (Tx Date) | Security | Quantity | Exercise Price | Post-Grant Options Held | Vesting |
|---|---|---|---|---|---|
| Aug 4, 2025 | Stock Option | 50,000 | $1.33 | 50,000 [2025-08-06 filing] | Not disclosed in Form 4 |
| Nov 3, 2025 | Stock Option | 5,000 | $3.075 | 55,000 [2025-11-05 filing] | Not disclosed in Form 4 |
Other Directorships & Interlocks
- No other public company boards disclosed for Parikh; no interlocks noted with competitors, suppliers, or customers .
Expertise & Qualifications
- Education: B.S. Biology (NJIT); MPH (Rutgers) .
- Technical/industry: Clinical research, trial management, and life sciences operations experience .
- Board qualifications: Practical clinical trial management background; independent status under Nasdaq rules .
Equity Ownership
Beneficial ownership (record date August 26, 2025):
| Holder | Common Shares | Options Exercisable | Unvested Options | Total Beneficial | % of Outstanding |
|---|---|---|---|---|---|
| Sanam Parikh | 1,770 | 25,000 | 25,000 (excluded from beneficial calc) | 26,770 | <1% |
| Shares outstanding | 5,903,437 | — | — | — | — |
Additional insider activity and current positions:
- Open market purchases: 770 shares at $1.30 (May 15, 2025); 1,000 shares at $1.45 (June 20, 2025), bringing reported common shares to 1,770 as reflected later in the special proxy .
- Anti-hedging/pledging: Company policy prohibits hedging/derivatives and pledging absent pre-clearance; as of Dec 31, 2024, no pledging by directors/officers .
Insider Trades (Form 3/4 summary)
| Filing Date | Transaction Date | Type | Security | Quantity | Price | Post-Transaction Ownership | SEC Link |
|---|---|---|---|---|---|---|---|
| 2024-12-02 | 2024-11-20 | Form 3 | — | — | — | Initial filing | |
| 2025-05-16 | 2025-05-15 | Purchase | Common Stock | 770 | $1.30 | 770 | |
| 2025-06-23 | 2025-06-20 | Purchase | Common Stock | 1,000 | $1.45 | 1,770 | |
| 2025-08-06 | 2025-08-04 | Award (Option) | Stock Option | 50,000 | $1.33 | 50,000 options | |
| 2025-11-05 | 2025-11-03 | Award (Option) | Stock Option | 5,000 | $3.075 | 55,000 options |
Related Party Transactions and Conflicts
- The company reported no related party transactions above the applicable threshold for 2023–2024; policy requires audit committee review/approval of any related-party dealings .
- No disclosed business dealings involving Parikh or family members; no director selection arrangements with third parties .
Governance Assessment
- Strengths: Independent status; relevant clinical trial management expertise; insider open-market share purchases in 2025 indicate alignment; no pledging/hedging and no related-party involvement disclosed .
- Concerns/RED FLAGS:
- Board turnover and Parikh’s resignation tied to November 2025 financing/events; while no disagreement was cited, turnover around capital events can signal governance fluidity .
- Limited public company board tenure and no disclosed committee leadership, reducing direct visibility into committee effectiveness .
- Equity plan amendments significantly increased share reserve; while not specific to Parikh, dilution risk and equity-heavy incentives warrant monitoring for director/management alignment and shareholder interests .
Notes:
- Appointment to the Board: November 20, 2024 .
- Resignation from the Board: November 6, 2025, not due to disagreement .
- Beneficial ownership footnotes detail option vesting/exercisability for Parikh as of the August 26, 2025 record date (25,000 exercisable; 25,000 unvested excluded) .
